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Abstract
Background: The treatment of leishmaniasis relies mostly on parenteral drugs with potentially serious adverse effects.
Additionally, parasite resistance in the treatment of leishmaniasis has been demonstrated for the majority of drugs available,
making the search for more effective and less toxic drugs and treatment regimens a priority for the control of leishmaniasis.
The aims of this study were to evaluate the antileishmanial activity of raloxifene in vitro and in vivo and to investigate its
mechanism of action against Leishmania amazonensis.
Methodology/Principal Findings: Raloxifene was shown to possess antileishmanial activity in vitro against several species
with EC50 values ranging from 30.2 to 38.0 mM against promastigotes and from 8.8 to 16.2 mM against intracellular
amastigotes. Raloxifene’s mechanism of action was investigated through transmission electron microscopy and labeling
with propidium iodide, DiSBAC2(3), rhodamine 123 and monodansylcadaverine. Microscopic examinations showed that
raloxifene treated parasites displayed autophagosomes and mitochondrial damage while the plasma membrane remained
continuous. Nonetheless, plasma membrane potential was rapidly altered upon raloxifene treatment with initial
hyperpolarization followed by depolarization. Loss of mitochondrial membrane potential was also verified. Treatment of
L. amazonensis – infected BALB/c mice with raloxifene led to significant decrease in lesion size and parasite burden.
Conclusions/Significance: The results of this work extend the investigation of selective estrogen receptor modulators as
potential candidates for leishmaniasis treatment. The antileishmanial activity of raloxifene was demonstrated in vitro and in
vivo. Raloxifene produces functional disorder on the plasma membrane of L. amazonensis promastigotes and leads to
functional and morphological disruption of mitochondria, which culminate in cell death.
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Introduction
With an incidence of two million new cases per year,
leishmaniasis is endemic in 98 countries and territories, repre-
senting an area where more than 350 million people are at risk of
acquiring the infection [1]. The treatment of leishmaniasis relies
mostly on parenteral drugs and involves high costs. Antimonial
compounds were discovered nearly 100 years ago and remain the
drug of choice for the treatment of leishmaniasis in many parts of
the world, despite their high toxicity and consequent severe
adverse effects. Amphotericin B and pentamidine are used as
second-line drugs, but their administration also involves serious
adverse effects [2]. Miltefosine has been approved for the therapy
of visceral leishmaniasis in India, but its efficacy for the treatment
of American leishmaniasis has been shown to be variable
depending on the causative species [3]. Moreover, parasite
resistance in the treatment of leishmaniasis was demonstrated for
the majority of drugs available [4]. Therefore, the search for more
effective and less toxic drugs and treatment regimens is a priority
for the control of leishmaniasis [5].
Screening of drugs originally developed for another purpose, or
drug repositioning, constitutes a promising strategy for the
discovery of new compounds effective against neglected diseases.
In the treatment of leishmaniasis, examples of this strategy are
miltefosine, initially developed for the treatment of breast cancer,
pentamidine, a hypoglycemic agent, as well as amphotericin B,
used in the treatment of fungal infections [6]. The benefits of
repositioning include the availability of materials and data such as
toxicology studies, resulting in reduction of time and costs to bring
the drug to the market [7].
Selective Estrogen Receptor Modulators (SERMs) are a class of
therapeutic agents widely prescribed for the treatment and
prevention of breast cancer, osteoporosis, and postmenopausal
symptoms [8]. The most widely used SERM is tamoxifen, a
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triphenylethylene used in the management of breast cancer. Due
to its mixed antagonist and agonistic estrogenic activity, long term
use of tamoxifen has been associated with an increased risk of
endometrial cancer in postmenopausal patients [9]. Drugs
belonging to a second class of SERMs built on a benzothiophene
scaffold are also in clinical use. One example of this second class is
raloxifene, an oral SERM which has estrogen agonist effects on
bone and cholesterol metabolism but behaves as a complete
estrogen antagonist on mammary gland and uterine tissue [10],
which results in skeletal benefit, with little, if any, uterine
stimulation [11].
Previous studies have shown that tamoxifen is active against
different species of Leishmania in vitro and in vivo [12,13,14]. In
infections caused by Leishmania amazonensis in BALB/c mice,
treatment with tamoxifen resulted in significant and sustained
improvement in both clinical and parasitological parameters [15].
The activity of this drug has also been demonstrated in
experimental infections by Leishmania braziliensis, the main causa-
tive agent of cutaneous leishmaniasis in Brazil. In this model,
tamoxifen was able to significantly reduce the size of lesions and
parasite burden [13]. Tamoxifen was also effective in the
treatment of infections caused by Leishmania major in a murine
model and in the treatment of visceral leishmaniasis in hamsters
infected with Leishmania infantum chagasi [13,14].
The activity of tamoxifen in the treatment of experimental
leishmaniasis led us to investigate whether raloxifene also presents
leishmanicidal effect. Here, we describe the antileishmanial
activity of raloxifene in vitro and in vivo and investigate its
mechanism of action against L. amazonensis, which is responsible
for most cases of human cutaneous leishmaniasis in the Amazon
region of Brazil [16].
Materials and Methods
Ethics statement
Animal experiments were approved by the Ethics Committee
for Animal Experimentation (Protocol 033/42/02) of the Bio-
medical Sciences Institute of the University of São Paulo. The
research adhered to the Brazilian Guidelines for Care and
Utilization of Animals from the Conselho Nacional de Controle
e Experimentação Animal (CONCEA).
Drugs
Raloxifene hydrochloride and miltefosine were purchased from
Sigma-Aldrich (St Louis, MO, USA). Stock solutions of raloxifene
(10 mM) and miltefosine (20 mM) were prepared in DMSO and
in sterile water, respectively, and kept at 220uC. Dilutions from
the stock solutions were done in culture media. For in vivo
experiments, fresh solutions of raloxifene were prepared in saline
or Cremophor A25 (Sigma-Aldrich).
Parasites and macrophages
Promastigotes of Leishmania (Leishmania) amazonensis (MHOM/
BR/1973/M2269), Leishmania (Leishmania) donovani (LD-15/
MHOM/SD/00), Leishmania (Leishmania) infantum chagasi
(MHOM/BR/1972/LD), Leishmania (Leishmania) major (MHOM/
IL/1981/Friedlin), Leishmania (Leishmania) mexicana (MHOM/BR/
1974/M2682) and Leishmania (Viannia) braziliensis (MHOM/BR/
1975/M2903) were maintained in M199 medium (Sigma-Aldrich)
supplemented with 10% heat-inactivated fetal calf serum (FCS)
(Invitrogen Corporation, NY, USA) and 0.25% hemin at 25uC. L.
braziliensis and L. infantum chagasi cultures were also supplemented
with 2% sterile male human urine. Promastigotes of a L.
amazonensis transgenic line expressing luciferase (LaLUC) were
grown in the same medium supplemented with 32 mg/mL G418
[17].
Amastigotes were purified from lesions as described [18].
Briefly, amastigotes were obtained from lesions induced in BALB/
c mice, about 8 to 12 weeks after intradermal inoculation of 16106
parasites in the hind footpads. Lesions were removed and
homogenized in phosphate-buffered saline (PBS); the suspension
was cleared of cell debris by centrifugation at 50 g for 8 min; the
supernatant was then washed three times in PBS and passed
through a 25-gauge needle. Amastigotes recovered from tissue
were resuspended in RPMI-1640 medium supplemented with
10% FCS, 2 mM glutamine and 50 mg/mL gentamicin and kept
at 33uC in a 5% CO2 atmosphere.
Bone marrow-derived macrophages (BMDM) were obtained
from BALB/c mice as previously described [19]. J774 macro-
phages were maintained in RPMI-1640 medium supplemented
with 10% FCS at 37uC in a 5% CO2-humidified incubator.
Evaluation of in vitro antileishmanial activity and
mammalian toxicity
Cell viability was evaluated in vitro by cultivating promastigotes
(56106 per well) or lesion-derived amastigotes (16107 per well) in
M199 or RPMI-1640 medium, respectively, supplemented with
10% FCS. Parasites were incubated in the presence of increasing
concentrations of raloxifene (7.75 to 62.0 mM for promastigotes
and 3.75 to 30.0 mM for intracellular amastigotes, assayed at a 1.5-
fold dilution) for 24 h. Miltefosine (assayed in concentrations
varying from 1.5 to 45.0 mM) was used as a control drug.
Quantification of viable cells was assessed either by cell counting
or by measuring the cleavage of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT; Sigma-Aldrich) as previously
described [20]. MTT cleavage was assessed in a microplate reader
(POLARstar Omega, BMG Labtech, Ortenberg, Germany) with a
reference wavelength of 690 nm and a test wavelength of 595 nm.
The activity of raloxifene was also evaluated against L.
amazonensis promastigotes (36107/mL) incubated in M199 medi-
um or in Hank’s balanced salt solution supplemented with 10 mM
D-glucose (HBSS+Glc) (137 mM NaCl, 5.3 mM KCl, 0.4 mM
KH2PO4, 4.2 mM NaHCO3, 0.4 mM Na2HPO4, pH 7.2,
10 mM D-glucose) for 2 hours. Quantification of viable cells was
assessed by measuring the cleavage of (3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)
with the CellTiter 96 Aqueous One Solution Cell Proliferation
Assay (MTS, Promega), according to the manufacturer’s
instructions.
Author Summary
Cutaneous and visceral leishmaniasis are part of the group
we call neglected diseases. They are serious conditions
that afflict millions in vast regions of the world. These
diseases are very difficult to treat. This is due to the scanty
choice of effective drugs together with their potentially
severe side effects. One way of finding new treatments for
these neglected conditions is to repurpose drugs that are
already in use to treat other diseases. In this paper, we
show that raloxifene, a drug that is used for the treatment
of osteoporosis and also as an alternative in the treatment
of breast cancer, is active against the causative agents of
leishmaniasis and is effective in the treatment of cutane-
ous leishmaniasis in an experimental model. We also show
that the antileishmanial mechanism of action of raloxifene
is related to damage to the cell membrane and to the
mitochondrion of the parasite.
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The half maximal effective concentrations (EC50) were deter-
mined from sigmoidal regression of the concentration-response
curves using GraphPad Prism 5.0 software. Assays were performed
in triplicate and results are expressed as the mean and standard
deviation (SD) of at least three independent experiments.
In vitro cytotoxicity was evaluated by cultivating J774 macro-
phages (56105 per well) in 24-well plates for 24 h in the presence
of increasing concentrations of raloxifene. Cell viability was
assessed by the MTT assay as described above and results are
expressed as percentage reduction in cell viability compared with
untreated control cultures. The half maximal cytotoxic concen-
tration (CC50) was determined as described above for EC50 values.
The Selectivity Index of raloxifene was calculated as the ratio
between the CC50 for J774 macrophages and the EC50 against
Leishmania intracellular amastigotes.
Killing of intracellular L. amazonensis amastigotes was assayed by
analysis of parasite burden in BMDM monolayers. Macrophages
were plated on 96-well plates (86104 per well) in RPMI-1640
medium supplemented with 10% FCS and allowed to adhere
overnight at 37uC, at 5% CO2. LaLUC stationary-phase
promastigotes (in a ratio of 20 parasites: 1 macrophage) were
added to the wells and the cultures were incubated at 33uC in a
5% CO2 atmosphere. After 3 h, parasites were removed by
washing with RPMI-1640 medium and infected cultures were
treated with increasing concentrations of raloxifene or miltefosine
for 48 h. The monolayers were washed with PBS and luciferase
detection was performed with the One Glo Luciferase Assay
System (Promega Corporation), according to the manufacturer’s
instructions. Briefly, 20 mL of reagent at room temperature were
added to each well containing 100 mL of PBS followed by
homogenization. Luminescence units were determined immedi-
ately after adding the substrate in a Polarstar Omega reader (BMG
Labtech).
Drug activity against L. infantum chagasi intracellular amastigotes
was determined in BMDM infected macrophages in 16-well
chamber Slides (NUNC) (86104 per well) and infection was
carried out at 37uC as described above for L. amazonensis. For the
evaluation of parasite burden under light microscopy, 16-well
chamber slides were fixed in methanol and stained with the Instant
Prov kit (Newprov, Pinhais-Paraná, Brazil). The percentage of
infected macrophages was determined by counting 200 cells in
each of the replicates.
Transmission electron microscopy
Logarithmic-phase L. amazonensis promastigotes (26107/mL)
were incubated with 60 mM raloxifene for different periods of time
(30 min, 2 h and 14 h) at 25uC in M199 medium, supplemented
with 10% FCS, in 24-well plates. Subsequently, promastigotes
were centrifuged at 230 g for 10 min and the pellet was fixed in
2.5% glutaraldehyde : 4% paraformaldehyde in 0.1 M sodium
cacodylate buffer (pH 7.4), rinsed in the same buffer and post-
fixed in 1% osmium tetroxide, dehydrated in acetone series, and
embedded in Epon resin.
BMDM (46105 cells per well) were seeded in 24-well
microplates on ACLAR film (Electron Microscopy Sciences,
USA) cut into discs and allowed to adhere overnight at 37uC at
5% CO2. Infection with L. amazonensis promastigotes was carried
out at a ratio of 20:1 parasites per macrophage. Infected
macrophage cultures were kept at 33uC, 5% CO2 for 3 h in
RPMI 1640 medium with 10% FCS and then washed twice with
sterile PBS to remove free promastigotes. Infected cultures were
treated with 9 mM raloxifene for 48 hours. The medium was
removed and the monolayers were fixed as described above for
promastigotes.
Ultrathin sections were obtained in a Sorvall Ultramicrotome,
stained with uranyl acetate and lead citrate and observed under a
JEOL transmission electron microscope operating at 80 kV.
Images were recorded with a Gatan 785 ES1000W Erlangshen
camera. Parasites or infected macrophages without treatment were
used as a control.
Identification of autophagic vacuoles
Monodansylcadaverine (MDC) staining was used to label
autophagic vacuoles as previously described [21,22]. L. amazonensis
promastigotes (26107/mL) from early log phase cultures were
treated with 30 and 60 mM raloxifene for 30 min in M199
medium supplemented with 10% FCS, at 25uC. As a positive
control, parasites were subjected to starvation in PBS for 3 h [23].
Untreated parasites incubated in M199 medium for the same
period were used as a negative control. Following the incubation
period, cells were loaded with 100 mM MDC for 2 h. Cells were
washed four times in PBS and fixed in 4% paraformaldehyde. One
drop of fixed cells was added onto glass microscopic slides,
covered by a coverslip and immediately visualized in a Zeiss
AxioObserver microscope (Oberkochen, Germany) with excitation
and emission wavelengths of 358 and 463 nm respectively and
photographed using a digital camera (AxionCam HRc, Zeiss).
Twenty fields were randomly chosen from each sample (magni-
fication 6306 or 1,0006). Assays were performed in two inde-
pendent experiments.
Evaluation of plasma membrane integrity
L. amazonensis promastigotes (56106/mL) were treated with 30
and 60 mM raloxifene for 20 min or 2 h in M199 medium,
supplemented with 10% FCS at 25uC. Parasites treated with
25 mM digitonin were used as a positive control. Untreated
parasites and parasites incubated with the highest volume of
diluent (DMSO 0.6%) were used as negative controls. Parasites
were stained with 10 mM propidium iodide (PI) and immediately
analysed by flow cytometry using a Guava EasyCyte Mini Flow
Cytometer System (Millipore). A total of 5,000 events were
acquired in the region previously established as corresponding to
the parasites. Fluorescence was quantified using the CytoSoft 4.2.1
software (Guava Technologies Inc., Hayward, CA, USA).
Histograms were drawn using FlowJo software, version 9 for
Macintosh (Tree Star, Inc., Ashland, OR).
Assessment of plasma membrane electric potential
(DYp)
Estimation of DYp was monitored by measuring the increase in
absorbance of bis-(1,3-diethylthiobarbituric acid) trimethine ox-
onol [DiSBAC2(3)] (Invitrogen) as previously described [24].
Briefly, L. amazonensis promastigotes (26107/mL) were added into
black polystyrene 96-well microplates in HBSS+Glc containing
0.2 mM DiSBAC2(3) in a final volume of 100 mL per well. The
plate was incubated at 25uC in a microplate reader (POLARstar
Omega, BMG Labtech) and fluorescence was recorded
(lex = 544 nm; lem = 584 nm) every 2 min. After signal stabiliza-
tion raloxifene was added to final concentrations of 15, 30 or
60 mM. Gramicidin D 8 mM (Sigma-Aldrich) was used as a
positive control. Untreated parasites and parasites incubated with
the highest volume of diluent (DMSO 0.6%) were used as negative
controls. No interference in DiSBAC2(3) fluorescence was
observed when raloxifene was added to HBSS+Glc in the absence
of cells. Three independent experiments were performed, each one
with triplicate samples.
Antileishmanial Activity of Raloxifene
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Estimation of mitochondrial transmembrane electric
potential (DYm)
Changes in DYm were monitored by flow cytometry, using the
fluorescent dye rhodamine 123 (Rh123) (Sigma-Aldrich) as
previously described [24]. L. amazonensis promastigotes (26107/
mL) were resuspended in HBSS+Glc and incubated (1 mL final
volume) with increasing concentrations of raloxifene at 25uC for
20 min. After treatment, parasites were washed twice in HBSS+
Glc, loaded with Rh123 (0.3 mg/mL, 10 min, 37uC), washed twice
in HBSS+Glc and analysed by flow cytometry. Fluorescence
emission was quantified using the CytoSoft 4.2.1 software as
described above. Parasites depolarized with 100 mM carbonyl
cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP, Sigma-Al-
drich) were used as a positive control. Untreated parasites and
parasites incubated with the highest volume of diluent (DMSO
1.2%) were used as negative controls. Results were obtained from
three independent experiments.
Evaluation of raloxifene’s activity in vivo
Female BALB/c mice (4 to 5 weeks-old) were inoculated
intradermally with 16106 stationary-phase L. amazonensis promas-
tigotes at the proximal end of the tail, as described [12]. Three
weeks after infection, mice were randomly assigned into experi-
mental groups. In a first series of experiments (n = 2), mice infected
with wild type L. amazonensis were assigned to groups (n = 10) that
were either left untreated or received 40 mg/kg/day raloxifene by
oral gavage in 100 mL final volume of saline. Treated animals
received 10 doses of raloxifene, given on weekdays.
A second series of experiments (n = 2) was performed with mice
infected as described above, except for the use of the luciferase
expressing parasites, LaLUC. Treated groups (n = 5) received
100 mg/kg/day raloxifene prepared with Cremophor A25 (Sig-
ma-Aldrich) (100 mg/mL) by oral gavage in 100 mL final volume.
The control group received 100 mL of the vehicle used to dilute
raloxifene. All animals received 10 doses of the assigned scheme,
given on alternate days.
In both series of experiments, disease progression was evaluated
once a week by recording the average diameter of the tail
measured as the mean of tail base diameters in horizontal and
vertical directions. Measurements were taken with a caliper
(Mitutoyo Corp., Japan). For the second series of experiments,
parasite burden was evaluated at the end of the treatment (6 weeks
post-infection) through luciferase detection by bio-imaging (IVIS
Spectrum, Caliper Life Sciences, Inc. MA/USA) as described
[17]. Briefly, prior to imaging, mice received 75 mg/kg luciferin
(VivoGlo Luciferin, Promega) intraperitoneally. Imaging was
collected 20 min later, through high-resolution mode from a
fixed-size region of interest. Results were quantified with Living
Image software version 4.3.1 (Caliper Life Sciences), and results
were expressed as ph/sec/cm2/sr. Animal experiments were
approved by the Ethics Committee for Animal Experimentation
(Protocol 033/42/02).
Statistical analysis
In vitro data were analysed for statistical significance by One-way
ANOVA, followed by the Tukey post-test. Data on lesion
progression and parasite burden were analysed for statistical
significance by using the non-parametric Mann-Whitney test.
Statistical analyses were performed using GraphPad Prism 5
software.
Results
In vitro activity of raloxifene against Leishmania spp. and
mammalian cytotoxicity
The activity of raloxifene was tested initially against promasti-
gotes of different Leishmania species incubated in culture medium
supplemented with FCS. Sensitivity was uniform across the genus,
with EC50 values ranging from 30.2 to 38.0 mM after 24 h
incubation (Table 1).
Maximal effect was already observed after 2 h incubation with
raloxifene in M199 medium, with an EC50 value of 30.661.0 mM
against L. amazonensis promastigotes. The antileishmanial activity
was more pronounced when the assay was carried out in HBSS+
Glc, with an EC50 of 9.361.0 mM after 2 h incubation (Table 1).
Cytotoxicity against the host cells in vitro was determined using
cultures of J774 macrophages treated with raloxifene for 24 h with
calculated CC50 of 28.660.5 mM.
Drug activity was also tested ex vivo against L. amazonensis
amastigotes obtained from mice infected tissue allowing the
Table 1. Half maximal effective concentration (EC50) of raloxifene against Leishmania spp.
Leishmania species Stagea Condition (medium or buffer) Time of incubation (hours) EC50 ± SD
b
L. amazonensis P M199 24 30.261.7
L. amazonensis P M199 2 30.661.0
L. amazonensis P HBSS+Glc 2 9.361.0
L. braziliensis P M199 24 38.068.4
L. donovani P M199 24 32.561.3
L. infantum chagasi P M199 24 30.960.5
L. major P M199 24 32.661.4
L. mexicana P M199 24 30.361.3
L. amazonensis LA RPMI 24 15.062.3
L. amazonensis IA RPMI 48 16.262.2
L. infantum chagasi IA RPMI 48 8.861.1
aParasite form: P: promastigotes; LA: lesion derived amastigotes; IA: intracelullar amastigotes. Half maximal effective concentration against promastigotes and axenic
lesion-derived amastigotes was determined through MTT or MTS as described [20]; activity against L. amazonensis and L. infantum chagasi intracellular amastigotes was
determined through luciferase activity or microscopic counting, respectively, as described in Material and Methods.
bThe results are expressed as the mean and standard deviation (6 SD) of three independent experiments, each one performed in triplicate.
doi:10.1371/journal.pntd.0002842.t001
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Figure 1. Ultrastructural aspects in raloxifene treated Leishmania promastigotes and intracellular amastigotes. (A to F): Ultrathin
sections of L. amazonensis promastigotes. Promastigotes untreated (A) or incubated with 60 mM raloxifene for 30 min (B and C), 2 h (D and E) or 14 h
(F) in M199 observed under transmission electron microscopy. The structure indicated by the arrow in (B) is shown in higher magnification in the
Antileishmanial Activity of Raloxifene
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determination of an EC50 of 15.062.3 mM. Similar activity was
demonstrated when raloxifene was used to treat cultures of
BMDM infected with L. amazonensis or L. infantum chagasi (Table 1,
Figure S1). Raloxifene’s Selectivity Index varied between 1.76 and
3.24, for L. amazonensis and L. infantum chagasi intracellular
amastigotes, respectively.
The EC50 of miltefosine, a control standard drug against L.
amazonensis promastigotes and intracellular amastigotes was calcu-
lated as 16.861.7 mM and 2.760.3 mM, respectively, in agree-
ment with previously published data [25].
Ultrastructural alterations caused by raloxifene in L.
amazonensis promastigotes and intracellular amastigotes
Transmission electron microscopy was used to investigate the
effects of raloxifene on the parasite’s ultrastructure and morphol-
ogy. Untreated promastigotes showed typical ultrastructure
(Figure 1A) while parasites treated with raloxifene displayed
morphological alterations as early as 30 min after incubation with
the drug, when vacuoles similar to autophagosomes were observed
(Figure 1B and C, arrows). After 2 h, severe mitochondrial
damage was noted with marked swelling and loss of the matrix
content (Figure 1D and E, stars). In all cases the plasma membrane
seemed to be continuous. The absence of membrane disruption
was observed even in promastigotes treated with raloxifene for
14 h, which presented severe damage of the cytoplasm (Figure 1F).
In infected macrophages treated with raloxifene for 48 hours,
parasitophorous vacuoles were filled with remnants of vacuolated
cell bodies compatible with dead amastigotes (Figure 1H, arrow-
heads). The ultrastructure of intracellular amastigotes in infected
BMDM also displayed morphological alterations compatible with
the formation of autophagosomes (Figure 1I, arrow) and
mitochondrial swelling (Figure 1I, star).
Cells treated with raloxifene display autophagic vacuoles
MDC is considered a marker for the presence of autophago-
somes [26]. Raloxifene-treated promastigotes were labeled with
MDC and visualized by fluorescence microscopy. Spherical
structures stained by the dye were observed in parasites treated
with raloxifene for 30 min (Figure 2C and D), in contrast to the
weak and diffuse overall cytoplasmic staining in untreated
parasites (Figure 2A). PBS starvation was used as a known
inducer of autophagy [27]. In these conditions promastigotes
concentrated the label in round bodies (Figure 2B) with a
pattern similar to the one observed after treatment with
raloxifene.
Raloxifene does not disrupt L. amazonensis membrane
integrity
Membrane integrity can also be evaluated through permeation
of vital dyes such as PI. Permeation of PI in promastigotes treated
inset. (G to I): Ultrastructural morphology of intracellular amastigotes. BMDM were infected with L. amazonensis and cultured for 48 hours in the
absence (G) or in the presence of 9 mM raloxifene (H and I). (I) shows the same field as in (H) under higher magnification. Raloxifene induced the
formation of autophagosomes (arrows) and mitochondrial swelling (stars), with no disruption of the plasma membrane. Arrowheads indicate
remnants of vacuolated cell bodies compatible with dead amastigotes. N: nucleus; M: mitochondrion.
doi:10.1371/journal.pntd.0002842.g001
Figure 2. Monodansylcadaverine (MDC)-labeling of raloxifene-treated promastigotes. L. amazonensis promastigotes were incubated at
25uC in M199 medium (A), in PBS for 3 h (B), with 30 mM (C) or 60 mM raloxifene (D) in M199 medium for 30 min. Following the incubation period,
cells were labeled with MDC, observed by fluorescence microscopy and photographed under 6306magnification (A to C) or 1,0006magnification (D).
Prominent cytoplasmic MDC-labeled vacuoles are indicated by arrows. Images are representative of two independent experiments. The insets show
increased size images of cells displaying MDC-positive vacuoles.
doi:10.1371/journal.pntd.0002842.g002
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with raloxifene for 20 min or 2 h was measured by flow cytometry.
While parasites treated with 25 mM digitonin showed early and
pronounced increase in the uptake of PI, indicative of membrane
damage, treatment with 30 or 60 mM raloxifene did not induce
any significant changes in fluorescence after 20 min or 2 h
(Figure 3).
Raloxifene alters the DYp
To verify whether raloxifene alters plasma membrane functions
which could not be observed through transmission electron
microscopy or PI staining, DYp was monitored using DiSBAC2(3)
as a fluorescent probe. In cells loaded with the voltage sensitive
fluorescent dye, raloxifene induced an early decrease in fluores-
cence indicating membrane hyperpolarization (Figure 4). This
early effect was followed, after the first 5 min of treatment, by a
dose-related fluorescence intensity increase to reach levels
indicative of total depolarization after 30 min incubation. This
was confirmed by treatment with the nonselective ionophore
gramicidin, which only marginally increased the fluorescence in
cells previously treated with raloxifene while a significant increase
in fluorescence was noted in control untreated parasites.
Raloxifene induces loss of DYm
In order to confirm the mitochondrial damage observed under
transmission electron microscopy, the mitochondrial function was
evaluated using the fluorescent probe Rh123 by flow cytometry.
Parasites treated with increasing concentrations of raloxifene for
20 min exhibited a gradual inability to concentrate the dye,
indicating a progressive collapse of the DYm (Figure 5). The EC50
calculated based on Rh123 fluorescence was 9.4261.03 mM, in
accordance with the EC50 based on mitochondrial activity
measured in parasites incubated in HBSS+Glc for 2 h. The
mitochondrial protonophore FCCP was used as positive control of
mitochondrial membrane depolarization and induced a reduction
of 63.560.9% in Rh123 accumulation.
In vivo efficacy of raloxifene
Treatment of L. amazonensis-infected BALB/c mice was initiated
3 weeks post-infection and the progression of lesion thickness in
untreated and raloxifene-treated mice was recorded weekly. In a
first series of experiments, treated mice received 40 mg/kg/day
raloxifene orally for 10 doses on weekdays. Significant reduction in
lesion thickness in treated groups was noticed (Figure 6A). Five
weeks after the end of treatment, the average size of lesions in
treated groups was reduced by 41.7% as compared with control
mice. After the interruption of treatment, lesion size in treated
groups increased but did not reach sizes observed in control
untreated animals (Figure 6A).
In a second series of experiments, mice were treated with
100 mg/kg/day orally in a total of 10 doses in alternate days. In
this case, significant decrease in the lesion size was more
pronounced with a 54.3% reduction in the average lesion size of
treated mice five weeks after the end of treatment (Figure 6B and
C). In order to estimate the parasite burden in the site of infection,
light emission of LaLUC parasites was recorded at the end of
raloxifene treatment (6 weeks post-infection). Parasite burden was
reduced by 89.7% in the group treated with raloxifene when
compared with the untreated group, as indicated by biolumines-
cence quantification (Figure 6D and E). Untreated and vehicle-
treated groups were not significantly different (data not shown).
Discussion
The activity of the triphenylethilene tamoxifen against Leish-
mania, in vitro and in vivo was previously demonstrated [12,14,15].
Tamoxifen and raloxifene are classified as SERMs, a class of
compounds that exhibit agonist and antagonist estrogenic effects
depending on the target tissue. Here, we report that raloxifene – a
benzothiophene belonging to a SERM class distinct from
tamoxifen’s – also presents in vitro broad-spectrum activity against
Figure 3. Propidium iodide labeling after raloxifene treatment.
Parasites were incubated at 25uC in M199 medium, left untreated or
treated with 30 or 60 mM raloxifene and analysed upon addition of
propidium iodide. Parasites treated with 25 mM digitonin were used as a
positive control. Untreated parasites and parasites incubated with the
highest volume of drug diluent (DMSO 0.6%) were used as negative
controls. Fluorescence histograms are representative of three indepen-
dent experiments with untreated parasites (gray), 30 mM raloxifene
(blue), 60 mM raloxifene (red) or 25 mM digitonin (black) for 20 min (A)
or 2 hours (B). (C) Values shown are the mean fluorescence intensity 6
standard deviation of three independent experiments. (*) indicates
significant difference relative to the untreated group (p,0.0001). NT:
untreated; RAL: raloxifene.
doi:10.1371/journal.pntd.0002842.g003
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different Leishmania species. This is the first report of the activity of
raloxifene against protozoan parasites.
Tamoxifen has been shown to be strongly incorporated into
biomembranes, to disrupt membrane structure and to induce
mitochondrial permeabilization [28], characteristics that can be
correlated with its high hydrophobicity (LogP = 5.93) and are
estrogen receptor-independent. Raloxifene is also highly lipophilic
(LogP = 5.69) and possesses estrogen receptor independent activities
[29]. The observation of continuous plasma membrane ultrastruc-
ture as well as the lack of increased permeability to PI in raloxifene-
treated promastigotes indicated absence of membrane disruption.
On the other hand, more subtle membrane lesions can be
monitored using potential-sensitive fluorescent probes such as
DiSBAC2(3) which enters depolarized cells where binding to
intracellular proteins causes enhanced fluorescence. Interestingly,
treatment with raloxifene induced an early hyperpolarization
followed by dissipation of the membrane potential. The early event
may be due to fast ionic currents, observed as drug interaction with
the membrane takes place. This is followed by the collapse of ionic
gradients across the membrane leading to depolarization. At this
point, it is unclear whether the loss of membrane potential is due to
a disarrayed membrane structure or to inhibition of ion channels.
Interestingly, previous studies have shown that raloxifene
inhibits voltage dependent calcium currents in mouse spermato-
genic cells in an estrogen receptor independent way [30]. The
presence of a voltage gated calcium channel sharing several
characteristics with the human counterpart has been recently
demonstrated in the plasma membrane of Leishmania [31].
Accordingly, calcium channel blockers used as anti-hypertensive
drugs, have been shown to possess antileishmanial activity
[32,33,34]. Thus, interference in calcium channels in raloxifene
treated parasites cannot be ruled out.
Raloxifene was previously shown to decrease DYm in human
endometrial carcinoma cells [35]. In raloxifene-treated parasites we
Figure 4. Plasma membrane potential in raloxifene treated parasites. L. amazonensis promastigotes were equilibrated with 0.2 mM
DiSBAC2(3) in Hank’s balanced salt solution supplemented with glucose at 25uC. Fluorescence was recorded continuously (544 nm excitation, 584 nm
emission) and drugs were added at time 0. Cells were treated with 15, 30 or 60 mM raloxifene. At the end of the experiment (indicated by the arrow),
8 mM gramicidin was added to all wells. Traces are from one experiment representative of three independent experiments.
doi:10.1371/journal.pntd.0002842.g004
Figure 5. Mitochondrial membrane potential in raloxifene treated parasites. L. amazonensis promastigotes preincubated with raloxifene in
Hank’s balanced salt solution supplemented with glucose for 20 min were loaded with 0.3 mg/mL Rh123, and the fluorescence level was measured by
flow cytometry. Parasites treated with 100 mM FCCP were used as a positive control. Untreated parasites (NT) and parasites incubated with the
highest volume of drug diluent (DMSO 1.2%) were used as negative controls. (A) Representative fluorescence histograms with untreated parasites
(gray), 11 mM raloxifene (blue), 120 mM raloxifene (red) or 100 mM FCCP (black). (B) Mean fluorescence intensity compared to the control in parasites
treated with increasing concentrations of raloxifene. Bars represent the mean and standard deviation of triplicates in an experiment representative of
three independent experiments.
doi:10.1371/journal.pntd.0002842.g005
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observed severe mitochondrial damage by transmission electron
microscopy and Rh123 labeling. As a result, the energy-coupling
system in the mitochondria is most likely inactivated.
The observation of autophagic vacuoles by transmission
electron microscopy and the presence of MDC-labeling vacuoles
in raloxifene-treated promastigotes suggest the participation of
autophagy in raloxifene’s mode of action. This is in accordance
with previous findings indicating that SERMs induce autophagy in
tumor cells [36,37]. Autophagosomes and MDC-labeled vacuoles
have been previously described as effects of antileishmanial
compounds [38,39].
Previous to raloxifene-induced cell death, loss of mitochondrial
membrane potential and entrapment of cytoplasm content within
autophagosomes were noted. The presence of autophagic vacuoles is
most likely related to the degradation of damaged organelles induced
by raloxifene treatment. Based on the obtained results, we propose
the following sequence of events triggered by raloxifene: i) partition of
raloxifene in the plasma membrane; ii) alteration in plasma
membrane potential; iii) mitochondrial membrane depolarization;
iv) mitochondrial dysfunction; v) autophagy; vi) parasite death.
Raloxifene was developed as an anti-estrogen against breast cancer
and was later found out to be a therapeutic agent for postmenopausal
osteoporosis. Pharmacokinetic studies have shown good oral
absorption; glucuronide conjugates are formed after extensive first-
pass metabolism in the intestinal mucosa and liver. Acute toxicity is
low with no mortality observed with doses up to 5000 mg/kg orally in
mice and rats. Preclinical toxicology studies indicated that raloxifene
was well tolerated in repeated dose assays in mice, rats, dogs and
monkeys. In mice, daily doses of up to 120 mg/kg raloxifene for 3
months induced no serious toxic effects [40]. Based on this data, we
chose the starting oral dose of 40 mg/kg/day (3 times the human
dose for osteoporosis treatment and prevention, based on body
surface area) [41] for initial in vivo tests in a murine model of
cutaneous leishmaniasis. Treatment of L. amazonensis infected BALB/
c mice with raloxifene resulted in significant decrease in lesion size. As
the lesion in treated animals did not heal, we then increased the dose
Figure 6. Clinical follow up and determination of parasite burden in raloxifene-treated mice. BALB/c mice were infected with 16106
promastigotes at the proximal end of the tail. Treatment was initiated 3 weeks post-infection. (A) Mice infected with wild type L. amazonensis and
treated with 40 mg/kg/day raloxifene for 10 doses in weekdays (n = 10/group). (B–E) Mice infected with LaLUC and treated with 100 mg/kg/day
raloxifene in a total of 10 doses in alternate days (n = 5 per group). (A and B) Progression of lesion thickness (mean 6 standard deviation) in untreated
(circles) and raloxifene-treated mice (squares). The horizontal bar indicates the period of raloxifene administration. (C) Macroscopical aspect of the
lesion in representative animals from the untreated and treated groups. (D) Lesion bioluminescence (mean 6 standard deviation) recorded from
untreated and raloxifene-treated mice 6 weeks post-infection. (E) Bioluminescence imaging from untreated and raloxifene-treated mice 6 weeks post-
infection. Ph/sec/cm2/sr: photons per second per square centimeter per steradian. (*) p,0.01 in comparison with untreated group. Results shown are
from one experiment representative of two independent experiments.
doi:10.1371/journal.pntd.0002842.g006
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to 100 mg/kg/day. As the drug is poorly soluble in water, for this
second series of experiment raloxifene was prepared in Cremophor
A25, which is a vehicle capable of yielding stable emulsions of
hydrophobic, pharmacologically active biomolecules.
Treatment of L. amazonensis infected BALB/c mice with
100 mg/kg/day raloxifene resulted in significant decrease in
lesion size and parasite burden. No toxic effects were observed
during drug administration. Raloxifene-treated animals did not
heal the lesions completely and, after the interruption of
treatment, lesions worsened. However, these lesions did not reach
sizes observed in untreated controls. Since BALB/c mice infected
with L. amazonensis represents a model of extreme susceptibility, the
significant reduction in the number of parasites in treated animals
supports the proposal of further testing of this drug in other animal
models of leishmaniasis. Furthermore, these data warrant the
consideration of this molecule as a lead for further development.
In fact, recent results from our laboratory indicate that the
antileishmanial potency of synthetic benzothiophenes is increased
10-fold (as compared to raloxifene) by the presence of two basic
side chains in the molecule [42]. Furthermore, structure-activity
data showed that the most active antileishmanial benzothiophenes
lack the pharmacophore for estrogen receptor activity confirming
that the antileishmanial activity observed for benzothiophenes is
independent of the interaction with the estrogen receptors [42].
In conclusion, the results of this work extend the investigation of
SERMs as potential candidates for leishmaniasis treatment.
Raloxifene’s activity in vitro is mediated by functional damage to
the plasma and mitochondrial membranes, which culminate in cell
death. Further studies are necessary to ascertain whether other
antileishmanial mechanisms are engaged in vivo.
Supporting Information
Figure S1 Activity of raloxifene against intracellular L. infantum
chagasi amastigotes. BMDM were infected with stationary phase
promastigotes of L. infantum chagasi for 3 h. After washing the
remaining extracellular parasites, raloxifene was added to the
culture media. After 48 h incubation, slides were fixed and
stained. (A) Control untreated cells; (B) 3.75 mM; (C) 5.62 mM; (D)
7.5 mM; (E) 11.25 m; (F) 15 mM raloxifene. Bar = 10 mM.
(TIF)
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